Cocchieri Riccardo, van de Wetering Bertus, van Tuijl Sjoerd, Mousavi Iman, Riezebos Robert, de Mol Bastian
Cardiothoracic Surgeon, OLVG Hospital, 1091 AC Amsterdam, The Netherlands.
Biomedical Engineer, LifeTec Group BV, 5611 ZS Eindhoven, The Netherlands.
J Cardiovasc Dev Dis. 2022 Aug 11;9(8):261. doi: 10.3390/jcdd9080261.
Almost 30 years after the first endoscopic mitral valve repair, Minimally Invasive Mitral Valve Surgery (MIMVS) has become the standard at many institutions due to optimal clinical results and fast recovery. The question that arises is can already good results be further improved by an Institutional Risk Management Performance (IRMP) system in decreasing risks in minimally invasive mitral valve surgery (MIMVS)? As of yet, there are no reports on IRMP and learning systems in the literature. (2) : We described and appraised our five-year single institutional experience with MIMVS in isolated valve surgery included in the Netherlands Heart Registry (NHR) and investigated root causes of high-impact complications. (3) : The 120-day and 12-month mortality were 1.1% and 1.9%, respectively, compared to the average of 4.3% and 5.3% reported in the NHR. The regurgitation rate was 1.4% compared to 5.2% nationwide. The few high-impact complications appeared not to be preventable. (4) : In MIMVS, freedom from major and minor complications is a strong indicator of an effective IRMP but remains concealed from physicians and patients, despite its relevance to shared decision making. Innovation adds to the complexity of MIMVS and challenges surgical competence. An IRMP system may detect and control new risks earlier. (5) : An IRMP system contributes to an effective reduction of risks, pain and discomfort; provides relevant input for shared decision making; and warrants the safe introduction of new technology. Crossroads conclusions: investment in machine learning and AI for an effective IRMP system is recommended and the roles for commanding and operating surgeons should be considered.
在首次内镜二尖瓣修复近30年后,微创二尖瓣手术(MIMVS)由于其良好的临床效果和快速康复,已成为许多机构的标准术式。随之而来的问题是,机构风险管理绩效(IRMP)系统能否在降低微创二尖瓣手术(MIMVS)风险方面进一步提升已有的良好效果?截至目前,文献中尚无关于IRMP和学习系统的报道。(2):我们描述并评估了在荷兰心脏注册中心(NHR)登记的单纯瓣膜手术中,我们机构开展MIMVS的五年单中心经验,并调查了高影响并发症的根本原因。(3):120天和12个月死亡率分别为1.1%和1.9%,而NHR报道的平均死亡率分别为4.3%和5.3%。反流率为1.4%,而全国平均水平为5.2%。少数高影响并发症似乎无法预防。(4):在MIMVS中,无重大和轻微并发症是有效的IRMP的有力指标,但尽管其与共同决策相关,医生和患者仍对此并不了解。创新增加了MIMVS的复杂性,并对手术能力提出了挑战。IRMP系统可能更早地发现并控制新风险。(5):IRMP系统有助于有效降低风险、疼痛和不适;为共同决策提供相关信息;并保证新技术的安全引入。十字路口结论:建议投资于机器学习和人工智能以建立有效的IRMP系统,并应考虑主刀和操刀外科医生的角色。